These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 33936657)

  • 1. Anti-Programmed death-1 therapy in advanced hepatocellular carcinoma: A real-world experience.
    Al Jarroudi O; Chaabouni H; Ulusakarya A; Almohamad W; Gumus Y; Goldschmidt E; Afqir S; Morère JF
    Clin Case Rep; 2021 Apr; 9(4):2162-2167. PubMed ID: 33936657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Kuo HY; Han MZ; Liao CH; Lin YJ; Wang CT; Chen SH; Chang TT; Chen PJ; Lin SH; Chen CY; Chuang CH; Wu IC; Wu JS; Hong TC; Hsieh MT; Lee YC; Wu HT; Tsai HM
    Pharmaceutics; 2022 Oct; 14(11):. PubMed ID: 36365082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma.
    Sangro B; Melero I; Wadhawan S; Finn RS; Abou-Alfa GK; Cheng AL; Yau T; Furuse J; Park JW; Boyd Z; Tang HT; Shen Y; Tschaika M; Neely J; El-Khoueiry A
    J Hepatol; 2020 Dec; 73(6):1460-1469. PubMed ID: 32710922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Real-World Experience on a Chinese Population of Patients With Unresectable Hepatocellular Carcinoma Treated With Nivolumab.
    Lee SW; Yang SS; Lee TY
    Gastroenterology Res; 2024 Feb; 17(1):15-22. PubMed ID: 38463150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma.
    De Wilde N; Vonghia L; Francque S; De Somer T; Bagdadi A; Staub E; Lambrechts J; Bucalau AM; Verset G; Van Steenkiste C
    World J Hepatol; 2022 Aug; 14(8):1608-1620. PubMed ID: 36157862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nivolumab for the treatment of hepatocellular carcinoma.
    Chiew Woon L; Joycelyn Jie Xin L; Su Pin C
    Expert Opin Biol Ther; 2020 Jul; 20(7):687-693. PubMed ID: 32249635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study.
    Fessas P; Kaseb A; Wang Y; Saeed A; Szafron D; Jun T; Dharmapuri S; Rafeh Naqash A; Muzaffar M; Navaid M; Khan U; Lee C; Bulumulle A; Yu B; Paul S; Nimkar N; Bettinger D; Benevento F; Hildebrand H; Pressiani T; Abugabal YI; Personeni N; Huang YH; Rimassa L; Ang C; Marron T; Pinato DJ
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32868393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
    Scheiner B; Kirstein MM; Hucke F; Finkelmeier F; Schulze K; von Felden J; Koch S; Schwabl P; Hinrichs JB; Waneck F; Waidmann O; Reiberger T; Müller C; Sieghart W; Trauner M; Weinmann A; Wege H; Trojan J; Peck-Radosavljevic M; Vogel A; Pinter M
    Aliment Pharmacol Ther; 2019 May; 49(10):1323-1333. PubMed ID: 30980420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Cabozantinib and Nivolumab in Treating Hepatocellular Carcinoma with RET Amplification, High Tumor Mutational Burden, and PD-L1 Expression.
    Yang X; Shi J; Chen X; Jiang Y; Zhao H
    Oncologist; 2020 Jun; 25(6):470-474. PubMed ID: 32100934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Cell Death Protein-1 (PD-1)-Targeted Immunotherapy for Advanced Hepatocellular Carcinoma in Real World.
    Cui H; Dai G; Guan J
    Onco Targets Ther; 2020; 13():143-149. PubMed ID: 32021262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Xu HF; Gao QZ; Yang RJ
    Immunotherapy; 2021 Dec; 13(17):1395-1405. PubMed ID: 34607482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
    Kudo M
    Oncology; 2017; 92 Suppl 1():50-62. PubMed ID: 28147363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death protein 1 (PD-1)-inhibition in hepatocellular carcinoma (HCC): a single center experience.
    Mahn R; Vogt A; Kupczyk P; Sadeghlar F; van Beekum K; Hüneburg R; Meyer C; Toma M; Ahmadzadehfar H; Essler M; Matthaei H; Lingohr P; Kalff JC; Strassburg CP; Gonzalez-Carmona MA
    Scand J Gastroenterol; 2020 Sep; 55(9):1057-1062. PubMed ID: 32692941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of anti-PD-1 monotherapy
    Liu Q; Li R; Li L; Wang G; Ji S; Zheng X; Jia X; Tao H; Hu Y
    Ther Adv Med Oncol; 2023; 15():17588359231206274. PubMed ID: 37885459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
    Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
    Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA.
    Uhlig J; Stein S; Kim HS
    Future Oncol; 2022 May; 18(14):1691-1703. PubMed ID: 35172633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model.
    Sové RJ; Verma BK; Wang H; Ho WJ; Yarchoan M; Popel AS
    J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma.
    Kim CG; Kim C; Yoon SE; Kim KH; Choi SJ; Kang B; Kim HR; Park SH; Shin EC; Kim YY; Kim DJ; Chung HC; Chon HJ; Choi HJ; Lim HY
    J Hepatol; 2021 Feb; 74(2):350-359. PubMed ID: 32810553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB; Sangro B; Yau T; Crocenzi TS; Kudo M; Hsu C; Kim TY; Choo SP; Trojan J; Welling TH; Meyer T; Kang YK; Yeo W; Chopra A; Anderson J; Dela Cruz C; Lang L; Neely J; Tang H; Dastani HB; Melero I
    Lancet; 2017 Jun; 389(10088):2492-2502. PubMed ID: 28434648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
    Alden SL; Lim M; Kao C; Shu D; Singal AG; Noonan A; Griffith P; Baretti M; Ho WJ; Kamel I; Yarchoan M; Hsiehchen D
    Cancer Res Commun; 2023 Jul; 3(7):1312-1317. PubMed ID: 37484200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.